Trial Profile
An Eight-Week, Randomized, Double-Blind, Parallel-Group, Pilot Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg in Comparison With Valsartan 320 mg in Patients With Mild to Moderate Hypertension During Exercise After a Missed Dose.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2012
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Valsartan
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.
- 29 Oct 2009 Actual patient number (68) added as reported by ClinicalTrials.gov.
- 29 Oct 2009 Actual end date (October 2009) added as reported by ClinicalTrials.gov.